|
The retrospective DUR program involves
reviews of patient drug history profiles generated from medical assistance paid claims
data by a panel of active practicing physicians and pharmacists. The reviews are based
upon predetermined standards consistent with the following:
| 1. |
American Medical Association Drug Evaluations; |
| 2. |
United States Pharmacopoeia-Drug Information; |
| 3. |
American Hospital Formulary Service Drug Information,
and |
| 4. |
Peer-reviewed medical literature. |
The retrospective review of the patient drug
history profiles by the panel of reviewers includes evaluation for:
| 1. |
Therapeutic appropriateness; |
| 2. |
Over and under utilization; |
| 3. |
Appropriate use of generic products; |
| 4. |
Therapeutic duplication; |
| 5. |
Drug-disease contraindications; |
| 6. |
Drug-drug interactions; |
| 7. |
Incorrect dosage or duration of therapy; and |
| 8. |
Clinical abuse/misuse. |
Pharmacy Point-of-Sale
|
